



MABTHERA[®] (RITUXIMAB)

*A comparison card to differentiate between the two formulations of
MabThera[®] (subcutaneous and intravenous)*

This leaflet has been produced by Roche for physicians, nurses and pharmacists for the safe and efficient use of MabThera[®] solution for subcutaneous injection (referred to as MabThera[®] SC) in patients with CLL and NHL




Please make sure that you select the correct MabThera® formulation

SUBCUTANEOUS INJECTION

*For use in Non-Hodgkins Lymphoma ONLY**

MabThera® 1400 mg solution for subcutaneous injection



**Withdraw directly from the vial
and administer by subcutaneous
injection** 

Check for the specific MabThera® SC packaging characteristics before use:

1. Red labelling: 'For subcutaneous use only', 'solution for subcutaneous injection' and 'SC'
2. Pink flip-off cap

INTRAVENOUS INFUSION

For use in all MabThera®-approved indications

MabThera® 100 mg concentrate for solution for infusion
MabThera® 500 mg concentrate for solution for infusion
For use in all MabThera-approved indications



**Dilute with 0.9% NaCl or 5%
glucose and administer by intravenous infusion**

Check for the specific MabThera® IV packaging characteristics before use:

1. Grey labelling: 'For intravenous use only', 'solution for infusion'
2. Grey flip-off cap



Please refer to the approved package insert for further information.